Inspira Technologies (IINN) has scaled-up its production capabilities for its U.S. Food and Drug Administration-cleared INSPIRA ART100 system, in response to expected demand from a European governmental authority with which the Company is currently in advanced-stage procurement negotiations. Inspira has ramped up strategic production in order to meet near-term delivery needs as Inspira expects these negotiations move toward finalization. The ART100 system, already implemented in clinical settings in the United States, is gaining traction as a reliable device for a critical care and emergency preparedness programs.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IINN:
- Inspira Technologies initiated with a Buy at Litchfield Hills
- Inspira Technologies Announces Shareholder Meeting to Address Nasdaq Compliance
- Inspira Technologies Launches Global Rollout of ART100 System
- Inspira initiates global commercial rollout of ART100 system
- Inspira Technologies Restructures Executive Team for Strategic Alignment
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue